Date de publication: 22 février 2021
Promoteur – Intermédiaire FinancierBIOVERSYS AG
The project supports the company's research and development (R&D) investments in the field of antimicrobial resistance, in particular tuberculosis and nosocomial infections. By targeting hospital-acquired infections the project also addresses COVID-19, as such co-infections very often occur in hospitalised COVID-19 patients, leading to serious complications.
The project supports a clinical-stage biopharmaceutical company focusing on the treatment of anti-microbial resistance. The objective is to further advance the product, conduct additional clinical studies to validate the product and obtain regulatory approval. The proposed transaction will enable the Promoter to address one of the highest unmet medical needs for new treatments against life-threatening resistant bacterial infections and chronic inflammatory microbiome disorders. The project aims to increase the overall survival rate and quality of life of patients. In addition, it will encourage the growth and development of European scientific acumen.
- Industrie - Industrie manufacturière
Montant BEI envisagé (montant approximatif)
EUR 20 million
Coût total (montant approximatif)
EUR 49 million
The investment activities such as research, development and clinical studies are expected to be carried out in existing authorised facilities. Therefore, it would not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending 2011/92/EU. Full environmental details verified during the appraisal.
Passation des marchés
The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services verified details during the project due diligence.
Signé - 26/03/2021